Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Outlook Therapeutics is a biopharmaceutical company developing ophthalmic formulations of bevacizumab for retinal diseases like wet AMD, DME, and BRVO. Its flagship product, ONS-5010/LYTENAVA, is approved in the EU and UK and aims to provide a safe, effective, and affordable on-label alternative to off-label repackaged bevacizumab. The company focuses on regulatory approval, strategic collaborations, and targeted commercialization in global markets.
This description was generated via AI from an annual report. Updated about 1 year ago.